Faricimab offers comparable efficacy and safety to current treatments for neovascular age-related macular degeneration (nAMD), while showing increased durability, according to real-world data presented at EURETINA Congress 2023.
This multi-center, prospective study delved included 670 eyes from 584 patients diagnosed with nAMD. The investigation encompassed both treatment-naïve individuals and those who transitioned from other anti-VEGF agents.
Of the 475 eyes with followed-up after 1 faricimab injection, there was a +0.98 letter improvement in best-corrected visual acuity (BCVA) (P = 0.025). A significant decrease in central subfield thickness (CST) at -30.99μm (p<0.00001) was observed, along with subretinal or intraretinal fluid (SRF or IRF) resolution rates of 33.6% and 15.1%.
Among the 287 eyes switched from aflibercept (AFL) after 1 faricimab injection, a BCVA increase of +0.36 letters (p=0.75) was reported, accompanied by a CST reduction of -25.73μm (P < 0.00001), and SRF/IRF resolution rates of 32.0% and 9.4%.
For eyes assessed after 3 faricimab injections (n = 213), an increase of +3.17 letters (P = 0.001) was achieved. Moreover, CST exhibited a substantial decrease of -45.04μm (P < 0.00001), while SRF/IRF resolution rates stood at 38.1% and 31.1%, respectively. Eyes that switched from AFL after three 3 injections (n = 140) experienced a BCVA increase of +2.89 letters (P = 0.008), a CST decrease of -40.74μm (P = 0.00007), and SRF/IRF resolution rates of 37.3% and 15.7%, respectively.
Of the 1882 injections administered, only 6 cases of inflammation were reported.
Reference
Almeida D. The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study. Presented at: EURETINA Congress 2023.
Related Content
